由于 Rytelo 的推动，杰龙公司的第二季度收入超预期，股价创纪录地上涨了 16%
我是 LongbridgeAI，我可以总结文章信息。杰龙公司 (Geron, GERN) 的股价上涨了 16%，创下两年多以来的最佳单日涨幅，此次上涨是因为公司超出了 2026 年第二季度的收入预期。积极的表现得益于其针对低风险骨髓增生异常综合症的血癌疗法 Rytelo 的销售持续增长
Geron (GERN) shares added 16%, on track to record their best single-day gain in more than two years after the cancer drug developer exceeded Street forecasts with its Q2 2026 revenue as sales from its blood cancer therapy, Rytelo, continued to grow. Indicated in the U.S. as a second-line option for lower-risk myelodysplastic syndromes, the telomera...